173 related articles for article (PubMed ID: 32897465)
1. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.
Çakır E; Saygın İ; Ercin ME
Turk J Med Sci; 2021 Aug; 51(4):1800-1808. PubMed ID: 33600097
[TBL] [Abstract][Full Text] [Related]
4. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of mismatch repair deficiency in sarcomas.
Doyle LA; Nowak JA; Nathenson MJ; Thornton K; Wagner AJ; Johnson JM; Albrayak A; George S; Sholl LM
Mod Pathol; 2019 Jul; 32(7):977-987. PubMed ID: 30765880
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
7. High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan.
Amayiri N; Tabori U; Campbell B; Bakry D; Aronson M; Durno C; Rakopoulos P; Malkin D; Qaddoumi I; Musharbash A; Swaidan M; Bouffet E; Hawkins C; Al-Hussaini M;
Int J Cancer; 2016 Jan; 138(2):380-5. PubMed ID: 26293621
[TBL] [Abstract][Full Text] [Related]
8. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
9. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
10. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract][Full Text] [Related]
11. A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.
Jang BS; Kim IA
Radiother Oncol; 2018 Aug; 128(2):245-253. PubMed ID: 29784449
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
13. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
14. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
[TBL] [Abstract][Full Text] [Related]
15. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.
Martin AM; Bell WR; Yuan M; Harris L; Poore B; Arnold A; Engle EL; Asnaghi L; Lim M; Raabe EH; Eberhart CG
J Neuropathol Exp Neurol; 2020 Jan; 79(1):74-85. PubMed ID: 31819973
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma.
Hölzl D; Hutarew G; Zellinger B; Schlicker HU; Schwartz C; Winkler PA; Sotlar K; Kraus TFJ
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2271-2280. PubMed ID: 33963441
[TBL] [Abstract][Full Text] [Related]
18. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.
Salem ME; Puccini A; Grothey A; Raghavan D; Goldberg RM; Xiu J; Korn WM; Weinberg BA; Hwang JJ; Shields AF; Marshall JL; Philip PA; Lenz HJ
Mol Cancer Res; 2018 May; 16(5):805-812. PubMed ID: 29523759
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
20. miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
Ashizawa M; Okayama H; Ishigame T; Thar Min AK; Saito K; Ujiie D; Murakami Y; Kikuchi T; Nakayama Y; Noda M; Tada T; Endo H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
Mol Cancer Res; 2019 Jun; 17(6):1403-1413. PubMed ID: 30872332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
